The 12 most common partnerships and co-selling mistakes and how to fix them for healthcare and life sciences in the Middle East
Every mistake we see teams make with partnerships and co-selling — starting with the ones that cost the most and are the cheapest to fix. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Middle East.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install partnerships and co-selling has to be shaped to that reality from day one.
Every partnerships and co-selling failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.
Mistake one, the foundational one: signing MOUs no one operationalises. Fix by naming an owner and writing kill criteria before you spend a dollar.
Mistake two: mistaking volume for progress. Fix by making sourced and influenced pipeline from partners the only weekly headline number.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.
Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.
Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.
Mistake five: ignoring the trigger. Partnerships and co-selling works when one great partner is worth ten marketing hires; without a real trigger the model is guesswork.
Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.
Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Partnerships · healthcare · Middle East — answered
- Does partnerships and co-selling work for healthcare and life sciences in the Middle East?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing. The healthcare teams that install this get past procurement instead of dying in it.
- What is the most expensive partnerships and co-selling mistake?
- Signing MOUs no one operationalises — because it silently degrades every downstream metric.
- Which mistake is cheapest to fix?
- Missing kill criteria. Write them in an hour and save a quarter of budget.
- Can I skip the quality gate?
- Not in the first four weeks. After the model is proven, you can automate parts of it.
- How do I know a mistake is compounding?
- Sourced and influenced pipeline from partners stalls or drops for two consecutive weeks. That is your alarm.
- What is the Middle East-specific pitfall when running partnerships and co-selling for healthcare?
- Importing a playbook that was built for another market. In the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing — the install has to reflect that.
Growth Broker editorial
Filed under partnerships · healthcare · middle east